IMAPAC Market Intelligence

A revolutionary milestone in healthcare through the power of cell and gene therapy: https://lnkd.in/gaF7zvtt 12-year-old Kendric Cromer has become the first patient to receive the newly approved gene therapy for sickle cell disease. After a long and difficult journey, he’s now on the path to a healthier, pain-free future. His story is a powerful reminder of the life-changing potential of medical breakthroughs and the hope they bring to families affected by this condition. Here’s to resilience, hope, and the future of gene therapy! #IMAPAC #IMAPACNews #GeneTherapy #SickleCellCure #HealthcareInnovation #InspiringStories #MedicalBreakthrough

Unlock the power of data-driven insights with IMAPAC! 🌐 With access to a global network of 80,000+ life science professionals, IMAPAC delivers real-time market intelligence that helps you stay ahead in the competitive world of pharma, biopharma, and life sciences. Whether you need tailored solutions or a partner with proven expertise, we’ve got you covered. 🎯 Flexibility to target your audience 🌍 Global reach 💼 Decade of expertise Ready to elevate your strategy? Download our comprehensive research now and achieve your goals faster. Visit our website today: https://lnkd.in/gFPDgb5g #LifeSciences #MarketResearch #Pharma #Biopharma #BusinessGrowth #IMAPACInsights #DataDriven

𝐈𝐌𝐀𝐏𝐀𝐂 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡: 𝐀𝐏𝐀𝐂 𝐁𝐢𝐨𝐩𝐡𝐚𝐫𝐦𝐚 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬 🌐 IMAPAC’s latest research across the APAC biopharma industry reveals key challenges with single-use bioreactors. 80% of companies cited Material Compatibility—especially leachables and extractables—as their primary concern, while 73% pointed to Scalability Issues. Dr. Pavithra Sudhakaran, Senior Market Research Analyst at IMAPAC, notes that material compatibility challenges are linked to product safety concerns, while scalability issues highlight the growing demand for flexible production solutions. Explore more insights on the APAC bioprocessing market. 👉 𝑫𝑶𝑾𝑵𝑳𝑶𝑨𝑫 𝑩𝑹𝑶𝑪𝑯𝑼𝑹𝑬: https://lnkd.in/gFPDgb5g #MarketIntellegence #Biopharma #Bioprocessing #SingleUseTechnology #MaterialCompatibility #Scalability #IMAPACResearch

𝗧𝗵𝗲 𝗙𝘂𝘁𝘂𝗿𝗲 𝗼𝗳 𝗕𝗶𝗼𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹𝘀 𝗶𝗻 𝗔𝘀𝗶𝗮! By 2032, Asia is set to surpass Europe as the second-largest market for single-use bioreactors. Underpinned by Dr. Pavithra Sudhakaran, IMAPAC's Senior Market Research Analyst, our analysis predicts a CAGR of 15% for Asia, driven by increased biologic demands, supportive government policies, and emerging manufacturing facilities in China, India, and South Korea. 🔍 𝗘𝘅𝗽𝗹𝗼𝗿𝗲 𝗜𝗻-𝗗𝗲𝗽𝘁𝗵 𝗠𝗮𝗿𝗸𝗲𝘁 𝗜𝗻𝘀𝗶𝗴𝗵𝘁𝘀 𝘄𝗶𝘁𝗵 𝗗𝗿. 𝗣𝗮𝘃𝗶𝘁𝗵𝗿𝗮’𝘀 𝗘𝘅𝗽𝗲𝗿𝘁𝗶𝘀𝗲: - Partnership & Collaboration Opportunities - Key Biopharma Sector Challenges - Trends in Mergers & Acquisitions - Analysis of Government and Private Sector Investments - Commercial Feasibility of New Products - Competitive Benchmarking - Growth Opportunities in Therapeutic Segments - Detailed Insights into the Bioreactors Market & Beyond! 🔗 𝗗𝗼𝘄𝗻𝗹𝗼𝗮𝗱 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗿𝗲𝗽𝗼𝗿𝘁 𝗵𝗲𝗿𝗲: https://lnkd.in/gFPDgb5g Learn how Dr. Pavithra Sudhakaran and the IMAPAC team, leveraging a network of over 80,000 life science professionals and a decade of expertise, tailor research that fits your exact needs. #Biopharma #Biotechnology #SingleUseBioreactors #MarketResearch #IMAPAC #DrPavithra

A staggering 56% of bioprocessing facilities in Korea rely on Contract Manufacturing Organizations (CMOs) for the production of their products. This significant reliance on CMOs stems from the absence of in-house manufacturing capabilities within these companies. Prominent firms such as ABL Bio, CHA Biotech, and Corestem are among those utilising CMOs to meet their production needs. This trend highlights the critical role CMOs play in the bioprocessing landscape, providing essential services that enable companies to bring their products to market efficiently. Would like to know more? Download Brochure Here: https://lnkd.in/gFPDgb5g #Bioprocessing #ContractManufacturing #LifeSciences #Biopharma #IMAPACmarketintelligence

Did you know that Germany is at the forefront of the European Biologics Contract Manufacturing Organization (CMO) landscape? 🇩🇪🔬 20% of the European Biologics CMO market is proudly based out of Germany! This statistic underscores Germany's pivotal role in driving innovation and excellence within the biologics industry. From cutting-edge research to state-of-the-art manufacturing facilities, Germany continues to spearhead advancements in biologics production, offering unparalleled expertise and infrastructure to support global healthcare initiatives. Would like to know more? Download Brochure Here: https://lnkd.in/gFPDgb5g #germany #CMO #europe #IMAPACmarketintelligence

Japan boasts a significant contribution, amounting to 20%, in the domain of Gene-Modified Cell Therapy procedures conducted within the APAC region. This remarkable involvement underscores the country's prominent role in advancing cutting-edge medical technologies. Among the key players in this field within Japan are renowned organisations such as San Bio, Healios, and Celgene KK, whose innovative contributions further amplify Japan's impact on the global stage of regenerative medicine. Would like to know more? Download Brochure Here: https://lnkd.in/gFPDgb5g #JapanHealthcare #GeneModifiedTherapy #APACMedicine #CuttingEdgeTech #SanBio #RegenerativeMedicine #InnovativeHealthcare

According to IMAPAC research, approximately 8% of the 638 drugs currently in development for oncology cell and gene therapy in APAC are attributed to Japan. This statistic underscores the significant contribution of Japanese companies to the advancement of innovative therapies in the field of oncology. Among the notable players shaping this landscape, companies such as Astellas, Medinet, and Takara Bio stand out for their pioneering work and dedication to transforming cancer treatment. Their commitment to research and development has led to the emergence of promising therapies that hold the potential to revolutionize cancer care. Would like to know more? Download Brochure Here: https://lnkd.in/gFPDgb5g #oncology #cellandgenetherapy #APAC #Japan #IMAPACmarketintelligence

Curious about where fellow industry professionals get their biopharma updates? Take a quick poll and let's uncover which social media platforms are the go-to sources for staying informed! #BiopharmaNews #IndustryInsights

Over the past five years, South Korea has established itself as a prominent hub track record of over 45+ facilities/companies dedicated to research, development, clinical trials, and manufacturing. Out of which more than 50% are specifically focusing their efforts on cell therapy.   Interested to know more about the South Korea Biopharma Market? Download Brochure Here: https://lnkd.in/gFPDgb5g #SouthKorea #celltherapy #IMAPACmarketintelligence